What is the appropriate pediatric dose of tranexamic acid for a child with Glanzmann thrombasthenia presenting with epistaxis?

Tranexamic Acid Dosing for Pediatric Epistaxis in Glanzmann Thrombasthenia

For a child with Glanzmann thrombasthenia presenting with epistaxis, administer tranexamic acid 10 mg/kg intravenously 3-4 times daily, or use topical tranexamic acid 500-1000 mg applied directly to the bleeding site.

Dosing Recommendations

Intravenous Administration

The FDA-approved dosing for tranexamic acid in hemophilia patients (which shares similar bleeding pathophysiology with Glanzmann thrombasthenia) is 10 mg/kg actual body weight administered 3-4 times daily intravenously 1. This dosing can be continued for 2-8 days as needed for hemorrhage control 1.

Critical administration details:

• Infuse no faster than 1 mL/minute to avoid hypotension 1
• Adjust dose for renal impairment if present 1
• This is for intravenous use only - never administer intrathecally as this can cause seizures and cardiac arrhythmias 1

Topical Administration

For epistaxis specifically, topical tranexamic acid is highly effective and may be preferred as first-line therapy. The evidence supports:

• 500-1000 mg topical TXA applied directly to the bleeding site 2
• The 1000 mg dose showed 2.9 times less bleeding at 5 minutes and 4.3 times less rebleeding compared to saline 2
• Can be mixed with saline and applied via cotton pledgets or nasal packing 3

Oral Administration

While not specifically addressed in the FDA labeling for this indication, oral TXA is used in clinical practice for Glanzmann thrombasthenia. Case reports document successful use of oral TXA started 1 day before procedures and continued for 3 additional days 4, though specific pediatric dosing for epistaxis is not well-established in the evidence provided.

Glanzmann Thrombasthenia-Specific Considerations

This condition requires special attention because:

• Standard hemostatic measures often fail - only 50% success with bovine collagen matrix and 35% with nasal packing alone 5
• Patients frequently require intensive care for life-threatening hemorrhage 5
• Repeated platelet transfusions lead to alloimmunization, making them progressively less effective 6, 7
• TXA helps reduce the need for platelet transfusions, which is critical in this population 6, 4

Treatment Algorithm

1. First-line: Apply topical TXA 1000 mg (crush tablet and mix with saline) directly to bleeding site with cotton pledgets 6, 2

2. If bleeding continues: Add IV TXA 10 mg/kg every 6-8 hours (3-4 times daily) 1

3. Concurrent measures:

   • Apply topical vasoconstrictors (oxymetazoline) 3
   • Consider nasal cautery with local anesthesia if bleeding site identified 3
   • Avoid bilateral cautery to prevent septal perforation 3

4. Refractory bleeding: May require platelet transfusion or recombinant factor VIIa, but reserve these to minimize alloimmunization risk 7, 8

Critical Pitfalls to Avoid

• Do not delay TXA administration - this population has severe bleeding risk and standard measures frequently fail 5
• Do not use excessive cautery - can damage nasal mucosa and worsen bleeding 3
• Monitor for thrombotic complications - TXA increases thrombosis risk, though this is rare in children 1, 9
• Ensure IV route only - intrathecal administration causes seizures 1
• Adjust for renal impairment if creatinine elevated 1

Evidence Quality Note

The FDA labeling provides clear IV dosing for hemophilia-related bleeding 1, which is directly applicable to Glanzmann thrombasthenia given similar platelet dysfunction. The topical TXA evidence for epistaxis is moderate quality 3, 2, but shows clear benefit with the 1000 mg dose demonstrating superior outcomes 2. The combination approach (topical + systemic) is supported by case reports in Glanzmann patients specifically 6, 4.